Roi Martin B. Pajimna

Roi Martin B. Pajimna

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 October 2025 in ACS Applied Nano Materials
Verified
Journal Article
Closed access
KAKhent Primo Alcantara
Khent Primo Alcantara
Roi Martin B. PajimnaRoi Martin B. Pajimna
Roi Martin B. Pajimna
PAPhilip Joshua Simon Aliga
Philip Joshua Simon Aliga
JMJohn Wilfred Malabanan
John Wilfred Malabanan
CTChawanvit Tangwongsiri
Chawanvit Tangwongsiri
PRPornchai Rojsitthisak
Pornchai Rojsitthisak

7 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Marlon III Cadauan MallillinMarlon III Cadauan Mallillin
Marlon III Cadauan Mallillin
Roi Martin B. PajimnaRoi Martin B. Pajimna
Roi Martin B. Pajimna
SZShengnan Zhao
Shengnan Zhao
MSMaryam Salami
Maryam Salami
Raimar LöbenbergRaimar Löbenberg
Raimar Löbenberg
Neal DaviesNeal Davies
Neal Davies
Oleosomes are submicron oil bodies of a triacylglycerol core enveloped by a phospholipid monolayer and embedded proteins, forming a naturally assembled nanocarrier with exceptional oxidative resilience, interfacial stability, and biocompatibility. Their unique architecture supports solvent-free extraction, self-emulsification, and near-complete encapsulation of highly lipophilic compounds (log P > 4), including curcumin and cannabidiol, with reported efficiencies exceeding 95%. These plant-derived droplets enhance oral bioavailability through lymphatic uptake and enable targeted delivery strategies such as magnetically guided chemotherapy, which has reduced tumor burden by approximately 70% in vivo. The review critically examines recent advances in oleosome research, spanning botanical sourcing, green extraction technologies, interfacial engineering, xenobiotic encapsulation, pharmacokinetics, and therapeutic applications across oncology, dermatology, metabolic disease, and regenerative medicine. Comparative analyses demonstrate that oleosomes rival or surpass synthetic lipid nanocarriers in encapsulation efficiency, oxidative stability, and cost efficiency while offering a sustainable, clean-label alternative. Remaining challenges, including low loading of hydrophilic drugs, allergenicity, and regulatory standardization, are addressed through emerging strategies such as hybrid oleosome–liposome systems, recombinant oleosin engineering, and stimulus-responsive coatings. These advances position oleosomes as a versatile and scalable platform with significant potential for food, cosmetic, and pharmaceutical applications.

8 October 2022 in Biology
Verified
Journal Article
Open access
PDF file
ALI FARHANALI FARHAN
ALI FARHAN
Ferry SaputraFerry Saputra
Ferry Saputra
MSMichael Edbert Suryanto
Michael Edbert Suryanto
FHFahad Humayun
Fahad Humayun
Roi Martin B. PajimnaRoi Martin B. Pajimna
Roi Martin B. Pajimna
Chung-Der HsiaoChung-Der Hsiao
Chung-Der Hsiao
The transparent appearance of fish embryos provides an excellent assessment feature for observing cardiovascular function in vivo. Previously, methods to conduct vascular function assessment were based on measuring blood-flow velocity using third-party software. In this study, we reported a simple software, free of costs and skills, called OpenBloodFlow, which can measure blood flow velocity and count blood cells in fish embryos for the first time. First, videos captured by high-speed CCD were processed for better image stabilization and contrast. Next, the optical flow of moving objects was extracted from the non-moving background in a frame-by-frame manner. Finally, blood flow velocity was calculated by the Gunner Farneback algorithm in Python. Data validation with zebrafish and medaka embryos in OpenBloodFlow was consistent with our previously published ImageJ-based method. We demonstrated consistent blood flow alterations by either OpenBloodFlow or ImageJ in the dorsal aorta of zebrafish embryos when exposed to either phenylhydrazine or ractopamine. In addition, we validated that OpenBloodFlow was able to conduct precise blood cell counting. In this study, we provide an easy and fully automatic programming for blood flow velocity calculation and blood cell counting that is useful for toxicology and pharmacology studies in fish.

8 January 2026 in Natural Product Research
Verified
Journal Article
Closed access
Roi Martin B. PajimnaRoi Martin B. Pajimna
Roi Martin B. Pajimna
Omar Atienza VillalobosOmar Atienza Villalobos
Omar Atienza Villalobos
SLStephen Lirio
Stephen Lirio
HHHsi-Ya Huang
Hsi-Ya Huang
Chia-Her LinChia-Her Lin
Chia-Her Lin
OVOliver Villaflores
Oliver Villaflores
Hypertension remains a major global health concern, highlighting the need for the development of safer and more efficacious antihypertensive agents. This study investigated the angiotensin-I converting enzyme (ACE-I) inhibitory activity of bioactive peptides derived from the African Nightcrawler earthworm, Eudrilus eugeniae (Kinberg, 1867) (E. eugeniae). Crude protein extracts were subjected to enzymatic hydrolysis using pepsin and pancreatin, followed by gel permeation chromatography for fractionation. Among the seven fractions, pooled fraction 6 (PF6), composed of peptides ranging from 917 to 1611 Da with 7-12 amino acid residues, exhibited the highest ACE-I inhibitory activity at 88.3% and an IC50 of 86.76 µg/mL. Peptide sequencing via MALDI TOF-MS/MS identified key sequences containing proline and hydrophobic residues, which may contribute to ACE-I inhibition. These findings suggest that E. eugeniae is a promising natural source of antihypertensive peptides.

23 September 2026 in ACS Omega
Verified
Journal Article
Open access
Roi Martin B. PajimnaRoi Martin B. Pajimna
Roi Martin B. Pajimna
JMJohn Wilfred Malabanan
John Wilfred Malabanan
NNNonthaneth Nalinratana
Nonthaneth Nalinratana
YSYilin Song
Yilin Song
PRPornchai Rojsitthisak
Pornchai Rojsitthisak
ALAgnes L. Llamasares-Castillo
Agnes L. Llamasares-Castillo
Vascular inflammation, marked by endothelial dysfunction and overexpression of proinflammatory cytokines such as interleukin-6 (IL-6) and monocyte chemoattractant protein-1 (MCP-1), is a key contributor to atherosclerosis. Oleuropein (Ole), a phenolic compound with proven anti-inflammatory properties, suffers from poor aqueous stability and limited oral bioavailability, constraining its clinical application. To overcome these limitations, we developed and optimized chitosan (CS)-coated liposomes for oral delivery of Ole. Using a Box-Behnken design, the optimized formulation exhibited a particle size of 168.73 ± 3.86 nm, a polydispersity index (PDI) of 0.17 ± 0.01, a moderate negative zeta potential (−22.50 ± 2.39 mV), an encapsulation efficiency of 87.17 ± 0.27%, and a loading capacity of 12.22 ± 0.25%. The CS-coated formulation retained acceptable colloidal stability under refrigerated storage, enabled pH-responsive sustained release governed by Fickian diffusion, and enhanced endothelial nanocarrier uptake in EA.hy926 cells. The formulation was well tolerated in vitro, with cell viability exceeding 90% across a 500–4000 ng/mL concentration range. In a TNF-α-induced murine model of acute vascular inflammation, daily oral administration of CS-Ole-Lip (20 mg/kg) significantly suppressed serum IL-6 by 6.90-fold (p < 0.05) and MCP-1 by 2.45-fold relative to TNF-α controls (p < 0.0001), with numerically greater suppression than that observed with free Ole and uncoated Ole-Lip at the same dose. CS-Ole-Lip at 2 mg/kg, one-tenth of the 20 mg/kg dose evaluated in this study, produced substantial serum cytokine suppression, suggesting a potential dose-sparing effect. No treatment-associated elevations in the evaluated serum markers of hepatic or renal function or overt histological abnormalities in the examined organs were observed. These findings support CS-Ole-Lip as a stable oral nanocarrier with enhanced anti-inflammatory pharmacodynamic activity. The mechanistic basis for the dose-sparing effect requires direct pharmacokinetic and molecular validation.